Drug Profile

Research programme: cancer therapeutics - PharmaMar

Alternative Names: MI 130004; MI 130110; PM050489; PM050489-trastuzumab; PM070311

Latest Information Update: 28 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PharmaMar
Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action CD13 antigen inhibitors; ERBB 2 receptor antagonists; Immunomodulators; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in Spain
02 Sep 2019 Preclinical development is ongoing in Cancer in Spain
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Spain

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com